Reported 4 days ago
Roche CEO Thomas Schinecker stated in a recent interview that the Swiss pharmaceutical company has no plans for job cuts and maintains a healthy business despite recent challenges in cancer drug development. He noted that the workforce is stable or slightly increasing, and the company's research budget remains consistent. While discussing future products, Schinecker mentioned the potential launch of an anti-obesity drug around 2029. He acknowledged ongoing economic difficulties in Europe, contrasting them with growth in the U.S.
Source: YAHOO